BiotechTube
FluoGuide

FluoGuide

Copenhagen, Denmark· Est.
fluoguide.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

FluoGuide is a Danish biotech company pioneering precision surgery through its uPAR-targeting fluorescent imaging agent, FG001. The company has successfully completed Phase II trials in aggressive brain cancer (high-grade glioma) and head & neck cancer, demonstrating clinical proof-of-concept. FluoGuide is advancing its pipeline towards Phase III and exploring therapeutic applications of its technology via photothermal treatment. The company is publicly listed on Nasdaq First North Growth Market and has secured strategic partnerships with industry leaders like Intuitive Surgical.

Oncology

Technology Platform

uPAR-targeting peptides conjugated to fluorescent dye (Indocyanine Green) for real-time cancer visualization during surgery and potential photothermal therapy.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The core opportunity is to establish FG001 as a new standard of care in cancer surgery, reducing recurrence rates and healthcare costs.
The partnership with Intuitive Surgical provides a direct route into the high-growth robotic surgery market.
The platform's potential applicability across up to 80% of solid tumors offers a significant expansion runway.

Risk Factors

Key risks include the inherent uncertainty of Phase III clinical trials and regulatory approval, despite promising Phase II data.
The company is pre-revenue and will require significant additional capital to fund late-stage development, creating dilution risk.
The surgical guidance market is competitive, requiring clear differentiation for commercial success.

Competitive Landscape

FluoGuide competes in the surgical oncology and fluorescence-guided surgery space. Competitors include non-targeted fluorescent agents (e.g., generic ICG, 5-ALA) and other companies developing targeted imaging agents. Its differentiation lies in the uPAR-targeting mechanism, which is highly specific to invasive cancer cells, and the dual diagnostic/therapeutic potential of its platform.

More companies in Diagnostics & Precision Medicine →More companies in Denmark →